Simvastatin improves diabetes-induced coronary endothelial dysfunction

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 386-395

  Tawfik, Huda E ^a   El Remessy, Azza B ^a   Matragoon, Suraporn ^a   Ma, Guochuan ^a   Caldwell, Ruth B ^a   Caldwell, R William ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ACETYLCHOLINE; APOCYNIN; ARGININE; DICHLOROFLUORESCEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SUPEROXIDE;

AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CELL LABELING; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME SYNTHESIS; HEART PROTECTION; MALE; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASODILATATION;

ANIMALS; ARGININE; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; STREPTOZOCIN; SUPEROXIDES; TYROSINE; VASODILATION;

EID: 33749019757     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.106823     Document Type: Article

References (40)

1. Beckman JA, Goldfine AB, Gordon MB, and Creager MA (2001) Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 103:1618-1623.
2. Borghi C, Dormi A, Veronesi M, Immordino V, and Ambrosioni E (2002) Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 4:277-285.
3. Chakraphan D, Sridulyakul P, Thipakorn B, Bunnag S, Huxley VH, and Patumraj S (2005) Attenuation of endothelial dysfunction by exercise training in STZ-induced diabetic rats. Clin Hemorheol Microcirc 32:217-226.
4. Chicoine LG, Paffet ML, Young TL, and Nelin LD (2004) Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol 287:L60-L68.
5. Cipolla MJ (1999) Elevated glucose potentiates contraction of isolated rat resistance arteries and augments protein kinase C-induced intracellular calcium release. Metabolism 48:1015-1022.
6. Cosentino F and Luscher TF (1998) Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32:S54-S61.
7. El-Remessy AB, Abou-Mohamed G, Caldwell RW, and Caldwell RB (2003) High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Investig Ophthalmol Vis Sci 44:3135-3143.
8. Gerson RJ, MacDonald J, Alberta AW, Kornbrust J, Majka JA, Stubbs J, and Bokelman DL (1989) Animal safety and toxicology of simvastatin and related hyroxy-ethylglutaryl-coenzyme A reductase inhibitors. Am J Med 87:S28-S38.
9. Gu K, Cowie CC, and Harris MI (1999) Diabetes and decline in heart disease mortality in U.S. adults. J Am Med Assoc 281:1291-1297.
10. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, Kemp BE, and Venema RC (2004) Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol 287:H560-H566.
11. Kaesemeyer HY, Caldwell RB, Huang J, and Caldwell RW (1999) Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. Am Coll Cardiol 33:234-241.
12. Kamata K, Kobayashi T, Matsumoto T, Kanie N, Oda S, Kaneda A, and Sugiura M (2005) Effects of chronic administration of fruit extract (Citrus unshiu MARC) on endothelial dysfunction in streptozotocin-induced diabetic rats. Biol Pharm Bull 28:267-270.
13. Kilbourn RG and Goldfarb RD (1999) Can nitric oxide production be modulated by altering L-arginine levels? Crit Care Med 27:2586-2587.
14. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010.
15. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, et al. (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 10:2356-2363.
16. Laufs U and Liao JK (1998) Post-transcriptional regulation of endothelial nitric-oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273:266-271.
17. Laufs U and Liao JK (2000) Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 10:143-148.
18. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, and Endres M (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942:23-30.
19. LIPID Study, The Long-Term Intervention with Pravastatin in Ischaemic Disease Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357.
20. Maguire SM, Nugent AG, McGurk C, Johnston GD, and Nicholls DP (1998) Abnormal vascular responses in human chronic cardiac failure are both endothelium dependent and endothelium independent. Heart 80:141-145.
21. Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, and Lechler RI (2000) Isolation of endothelial cells from murine tissue. J Immunol Methods 244:205-215.
22. Mercuro G, Zoncu S, Saiu F, Sarais C, and Rosano GM (2002) Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels. Am J Cardiol 90:747-750.
23. Milstien S and Katusic Z (1999) Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 263:681-684.
24. Ogonowski AA, Kaesemeyer WH, Jin L, Ganapathy V, Leibach FH, and Caldwell RW (2000) Effects of NO donors and synthase agonists on endothelial cell uptake of L-Arg and superoxide production. Am J Physiol 278:C136-C143.
25. Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, and Kasanuki H (2002) Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 54:395-399.
26. Pieper GM and Dondlinger LA (1997) Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther 283:684-691.
27. Pieper GM and Peltier BA (1995) Amelioration by L-arginine of a dysfunctional arginine nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 25:397-403.
28. Pitkanen OP, Nuutila P, Raitakari OT, Ronnemaa T, Koskinen PJ, Lida H, Lehtimaki TJ, Laine HK, Takala T, Viikari JS, et al. (1998) Coronary flow reserve is reduced in young men with IDDM. Diabetes 47:248-254.
29. Romero MJ, Platt DH, Caldwell RB, and Caldwell RW (2006) Does elevated arginase activity contribute to diabetes-induced endothelial dysfunction. (Abstract) FASEB J 20:A1125.
30. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, and Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J Am Med Assoc 285:1711-1718.
31. Shepherd J, Cobbe S, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307.
32. Sobrevia L and Mann GE (1997) Dysfunction of the endothelial nitric oxide signaling pathway in diabetes and hyperglycaemia. Exp Physiol 82:423-452.
33. Spolarics Z and Bond JS (1989) Comparison of biochemical properties of liver arginase from streptozocin-induced diabetic and control mice. Arch Biochem Biophys 274:426-433.
34. Stolk J, Hiltermann TJ, Dijkman JH, and Verhoeven AJ (1994) Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 11:95-102.
35. Sumi D, Hayashi T, Thankur NK, Jayachandran M, Asai Y, Kano H, Matsui H, and Iguchi A (2001) A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155:347-357.
36. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, and Lam KS (1999) Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 84:3212-3216.
37. Tsubouchia H, Inoguchia T, Sontaa T, Satoa N, Sekiguchia N, Kobayashia K, Sumimotob H, Utsumic H, and Nawataa H (2005) Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 39:444-452.
38. Wagner AH, Kohler T, Ruckschloss U, Just I, and Hecker M (2000) Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20:61-69.
39. Wassman S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, and Nickenig G (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300-305.
40. Wassman S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, and Nickenig G (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37:1450-1457.